Detalhe da pesquisa
1.
Safety and Tolerability of Subcutaneous IgPro20 at High Infusion Parameters in Patients with Primary Immunodeficiency: Findings from the Pump-Assisted Administration Cohorts of the HILO Study.
J Clin Immunol
; 41(2): 458-469, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33409867
2.
Safety and Tolerability of Manual Push Administration of Subcutaneous IgPro20 at High Infusion Rates in Patients with Primary Immunodeficiency: Findings from the Manual Push Administration Cohort of the HILO Study.
J Clin Immunol
; 41(1): 66-75, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33025378
3.
Long-Term Efficacy and Safety of Hizentra® in Patients with Primary Immunodeficiency in Japan, Europe, and the United States: a Review of 7 Phase 3 Trials.
J Clin Immunol
; 38(8): 864-875, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30415311
4.
Quantitative Evidence of Wear-Off Effect at the End of the Intravenous IgG (IVIG) Dosing Cycle in Primary Immunodeficiency.
J Clin Immunol
; 36(3): 210-9, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26910102
5.
Effect of time to treatment on response to C1 esterase inhibitor concentrate for hereditary angioedema attacks.
Ann Allergy Asthma Immunol
; 111(3): 211-5, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23987198
6.
Treatment response after repeated administration of C1 esterase inhibitor for successive acute hereditary angioedema attacks.
Allergy Asthma Proc
; 33(4): 354-61, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22856636
7.
Systemic IgG exposure and safety in patients with primary immunodeficiency: a randomized crossover study comparing a novel investigational wearable infusor versus the Crono pump.
Immunotherapy
; 14(16): 1315-1328, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36128795
8.
Safety and tolerability of IgPro10 in Japanese primary immunodeficiency patients: a registrational study.
Int J Hematol
; 113(6): 921-929, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33738703
9.
Tolerability of a new 10% liquid immunoglobulin for intravenous use, Privigen, at different infusion rates.
J Clin Immunol
; 30(3): 442-8, 2010 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-20217199
10.
Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency.
J Clin Immunol
; 30(5): 734-45, 2010 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-20454851
11.
Pharmacometric Analysis of IgPro10 in Japanese and Non-Japanese Patients With Primary Immunodeficiency.
Clin Ther
; 42(1): 196-209.e5, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31910997
12.
Pharmacokinetic Analysis of Weekly Versus Biweekly IgPro20 Dosing in Patients With Primary Immunodeficiency.
Clin Pharmacol Drug Dev
; 9(6): 664-670, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31814328
13.
Pharmacokinetic properties of Privigen® in Japanese patients with primary immunodeficiency.
Immunol Med
; 42(4): 162-168, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-31847720
14.
Privigen® has similar pharmacokinetic properties in primary and secondary immune deficiency.
Int Immunopharmacol
; 66: 119-126, 2019 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-30447530
15.
Factors motivating dyspepsia patients to enter clinical research.
Contemp Clin Trials
; 27(2): 103-11, 2006 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-16413229
16.
Omeprazole-induced slowing of gastrointestinal transit in mice can be countered with tegaserod.
Eur J Pharmacol
; 517(1-2): 127-31, 2005 Jul 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-15972210
17.
Recruitment index as a measure of patient recruitment activity in clinical trials.
Contemp Clin Trials
; 26(5): 552-6, 2005 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-15990360
18.
Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency.
Clin Pharmacokinet
; 50(6): 405-14, 2011 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21553933